China Biologic Products  reported record financial results for Q3 even though shipments of its blood-based products were lower than the year earlier. The secret? Albumin and other plasma-based products are in short supply in China, forcing China officials to allow prices to climb. In fact, China Biologic said the price of one product skyrocketed 425%. Counterfeiting forced regulators to crack down on all producers, restricting supplies still further.  More details...

Stock Symbol: (OTCBB: CBPO)